{
    "symbol": "HZNP",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 10:02:14",
    "content": " Your line is now open. We had many patients -- and I would say that the first quarter impact for infused medicines like TEPEZZA and KRYSTEXXA was around patients missing infusions, extending infusions, and then we worked through the first quarter to get people back on track and we're able to successfully do that. Norma, next question please. Your line is now open. Norma, next question, please. Norma, next question, please. Your line is now open. Norma, next question, please. Your line is now open. When we look at the prevalent market, as you've noted, we've talked about the annual incident population of 15,000 to 20,000, moderate to severe acute patients coming in each year, then we also talked about the -- about 70,000 subset of what is a several hundred thousand chronic population, and we define that as patients less than eight years that are most likely in the system that we can access and drive toward TEPEZZA. Norma, next question please. Your line is now open. Your line is open. Norma, next question please. Your line is open. Your line is open. I think our strategy for all promotion is to leverage the fact that you're going to significantly improved response with KRYSTEXXA plus immunomodulation, whether that's digital activities or consumer-related activities or physician-related activities, they'll all focus on that broader dataset within rheumatology, KRYSTEXXA methotrexate is a little over 50% and we see an opportunity to drive that across all those populations. Norma, next question please. Your line is now open. Your line is open."
}